Connect your AI

4D Molecular Therapeutics FDMT Price / book

Price / book at other companies

Eli LillyLLY

26.3×-20.7×

Regeneron PharmaceuticalsREGN

2.6×+0.2×

Vertex PharmaceuticalsVRTX

5.9×-1.7×

EyePoint, Inc. EYPT

4.7×+3.4×

AbbVieABBV

261×+221×

RegenxbioRGNX

20.5×+19.2×

Other financials

Income statement

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Profitability

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Calculated from 4D Molecular Therapeutics’s reported figures.

market cap/total stockholders equity=1.1×

Based on the most recent quarter.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is 4D Molecular Therapeutics's price / book?: 4D Molecular Therapeutics (FDMT) reported price / book of 1.1× in Q1 2026.
How has 4D Molecular Therapeutics's price / book changed year-over-year?: 4D Molecular Therapeutics's price / book increased by 230.4% year-over-year, from 0.3× to 1.1×.
What is the long-term trend for 4D Molecular Therapeutics's price / book?: Over 5 years (2020 to 2025), 4D Molecular Therapeutics's price / book has grown at a -27.8% compound annual growth rate (CAGR), from 4.3× to 0.8×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.